AR049063A1 - POSACONAZOL INJECTABLE PHARMACEUTICAL COMPOSITIONS WITH STABILIZED PARTICLES - Google Patents

POSACONAZOL INJECTABLE PHARMACEUTICAL COMPOSITIONS WITH STABILIZED PARTICLES

Info

Publication number
AR049063A1
AR049063A1 ARP050102203A ARP050102203A AR049063A1 AR 049063 A1 AR049063 A1 AR 049063A1 AR P050102203 A ARP050102203 A AR P050102203A AR P050102203 A ARP050102203 A AR P050102203A AR 049063 A1 AR049063 A1 AR 049063A1
Authority
AR
Argentina
Prior art keywords
posaconazol
pharmaceutical compositions
injectable pharmaceutical
stabilized particles
stabilized
Prior art date
Application number
ARP050102203A
Other languages
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049063(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR049063A1 publication Critical patent/AR049063A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Formulaciones utiles para tratar infecciones en una suspension inyectable que es estable cuando se la somete a la esterilizacion terminal por vapor. Reivindicacion 1: Una formulacion que comprende una suspension de posaconazol estabilizada por un fosfolípido, en una mezcla que contiene un protector térmico y un sistema tampon.Useful formulations to treat infections in an injectable suspension that is stable when subjected to terminal steam sterilization. Claim 1: A formulation comprising a posaconazole suspension stabilized by a phospholipid, in a mixture containing a thermal protector and a buffer system.

ARP050102203A 2004-05-28 2005-05-27 POSACONAZOL INJECTABLE PHARMACEUTICAL COMPOSITIONS WITH STABILIZED PARTICLES AR049063A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57512604P 2004-05-28 2004-05-28

Publications (1)

Publication Number Publication Date
AR049063A1 true AR049063A1 (en) 2006-06-21

Family

ID=34971355

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102203A AR049063A1 (en) 2004-05-28 2005-05-27 POSACONAZOL INJECTABLE PHARMACEUTICAL COMPOSITIONS WITH STABILIZED PARTICLES

Country Status (15)

Country Link
EP (1) EP1761247A1 (en)
JP (1) JP2008501034A (en)
KR (1) KR20070027564A (en)
CN (1) CN1988887A (en)
AR (1) AR049063A1 (en)
AU (1) AU2005249502A1 (en)
CA (1) CA2567803A1 (en)
IL (1) IL179627A0 (en)
MX (1) MXPA06013886A (en)
NO (1) NO20066005L (en)
PE (1) PE20060291A1 (en)
RU (1) RU2006146555A (en)
TW (1) TWI290051B (en)
WO (1) WO2005117831A1 (en)
ZA (1) ZA200609890B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060009469A1 (en) * 2004-05-28 2006-01-12 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmacutical compositions of posaconazole
LT2018164T (en) * 2006-05-12 2017-07-10 Christian Noe Use of combination preparations comprising antifungal agents
EP2130540A1 (en) 2008-06-02 2009-12-09 Sandoz AG Pharmaceutical compositions containing a crystalline form of posaconazole
EP2141159A1 (en) 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
US20120101277A1 (en) 2009-07-09 2012-04-26 Sandoz Ag Crystalline form of posaconazole
US9040539B2 (en) 2010-05-19 2015-05-26 Sandoz Ag Process for the preparation of chiral triazolones
US9206146B2 (en) 2010-05-19 2015-12-08 Sandoz Ag Purification of posaconazole and of posaconazole intermediates
EP2571868B1 (en) 2010-05-19 2016-05-04 Sandoz AG Preparation of posaconazole intermediates
JP5956980B2 (en) 2010-05-19 2016-07-27 サンド・アクチエンゲゼルシヤフト Process for the preparation of chiral compounds
HRP20211686T1 (en) * 2010-06-29 2022-03-04 Merck Sharp & Dohme Corp. Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
WO2012172015A1 (en) 2011-06-16 2012-12-20 Sandoz Ag Process for the preparation of a chiral compound
CN103284959B (en) * 2012-02-22 2015-06-03 重庆圣华曦药业股份有限公司 Posaconazole freeze-dried powder injection and preparation method thereof
CN102755628B (en) * 2012-07-16 2013-10-23 中国科学院微生物研究所 Antifungal pharmaceutical composition
CN102805731B (en) * 2012-08-22 2014-04-30 北京莱瑞森医药科技有限公司 Posaconazole dry suspension and preparation method thereof
CN105030668B (en) * 2015-06-26 2018-03-27 济川药业集团有限公司 Oral posaconazole supensoid agent and preparation method thereof
CN106333925B (en) * 2015-07-10 2019-06-18 上海美悦生物科技发展有限公司 A kind of posaconazole liquid suspension and preparation method thereof
CN105997872B (en) * 2016-07-08 2019-02-19 河南省立眼科医院 A kind of antimycotic solution of ophthalmically acceptable nano-micelle containing posaconazole
CN110582264B (en) * 2017-03-26 2022-11-11 V·R·斯塔福德 Method for treating eyelid skin condition
WO2018191541A1 (en) * 2017-04-12 2018-10-18 Bhagwandin Vikash J Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors
CN110507609B (en) * 2018-05-21 2021-09-17 上海医药工业研究院 Preparation method of posaconazole oral suspension
CN111514146A (en) * 2020-04-28 2020-08-11 山西振东泰盛制药有限公司 Pharmaceutical composition containing posaconazole
CN113933131B (en) * 2021-09-24 2024-01-26 合肥天一生物技术研究所有限责任公司 Vaginal microorganism fluorescent staining solution

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
WO2002080678A1 (en) * 2001-04-03 2002-10-17 Schering Corporation Antifungal composition with enhanced bioavailability

Also Published As

Publication number Publication date
WO2005117831A1 (en) 2005-12-15
TW200609001A (en) 2006-03-16
AU2005249502A1 (en) 2005-12-15
JP2008501034A (en) 2008-01-17
IL179627A0 (en) 2007-05-15
CA2567803A1 (en) 2005-12-15
CN1988887A (en) 2007-06-27
ZA200609890B (en) 2008-09-25
TWI290051B (en) 2007-11-21
EP1761247A1 (en) 2007-03-14
RU2006146555A (en) 2008-07-20
PE20060291A1 (en) 2006-04-14
MXPA06013886A (en) 2007-01-26
NO20066005L (en) 2007-02-27
KR20070027564A (en) 2007-03-09

Similar Documents

Publication Publication Date Title
AR049063A1 (en) POSACONAZOL INJECTABLE PHARMACEUTICAL COMPOSITIONS WITH STABILIZED PARTICLES
CL2015001974A1 (en) (divisional sol. 1567-2013) combinations of active ingredients comprising pyridylethylbenzamides and other active ingredients.
UY31209A1 (en) USE OF HOMO AND COPOLIMEROS FOR THE STABILIZATION OF FORMULATIONS OF ACTIVE PRINCIPLES
AR059350A1 (en) PHARMACEUTICAL FORMULATION FOR AEROSOLS WITH TWO OR MORE ACTIVE PRINCIPLES AND AT LEAST A TENSIOACTIVE SUBSTANCE
CL2009001874A1 (en) Use of bacillus subtilis qst713 nrrl b-21661 to formulate a probiotic composition for an animal; and probiotic composition of bacillus subtilis qst713 nrrl b-21661.
BRPI0508540A (en) compound, pharmaceutical composition, and use of a compound
MX2009003030A (en) Galenic form for the trans-mucosal delivery of active ingredients.
AR064614A1 (en) PRODUCT COMBINED TO CONTROL PARASITES IN ANIMALS
BR112015023922A2 (en) pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of using these
BRPI0714417B8 (en) method for making an oral care, personal care, cleanser and / or home care composition
AR043863A1 (en) COMPOSITIONS CONTAINING PIPERACILIN AND TAZOBACTAM, USEFUL FOR INJECTION
CL2018001420A1 (en) Treatment of cognitive disorders with (r) -7-chloro-n- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide and pharmaceutically acceptable salts thereof. (divisional application 201701853)
RS51185B (en) Compositions for vaginal use
DE602006014990D1 (en) INTRANASAL ADMINISTRATION OF FAST-ACTING INSULIN
PE20081003A1 (en) ENHANCED STABILITY LIQUID PHENYLPHRINE COMPOSITIONS
ECSP077387A (en) COMPOSITIONS CONTAINING PIPERACILIN, TAZOBACTAM AND AN AMINOCARBOXYL ACID IN A SODIUM LACTATE DILUENT
ES2722201T3 (en) Compositions and procedures useful for stabilizing protein-containing formulations
BRPI1009842B8 (en) use of tlr9 agonist and tlr2/6 agonist in the preparation of a pharmaceutical composition for treating, inhibiting or attenuating a microbial infection, as well as a pharmaceutically acceptable composition comprising said agonists
AR052162A1 (en) STABILIZED INJECTABLE PHARMACEUTICAL COMPOSITIONS WITH POSACONAZOL PARTICULATES
FI964285A (en) Pharmaceutical preparations based on derivatives belonging to the taxane class
BR112015005347A2 (en) compound, pharmaceutical composition, and method for treatment or prophylaxis of HIV infection or for treatment, prophylaxis, or delay in the onset of AIDS
BR0214497A (en) Pharmaceutical composition comprising a 5ht1 receptor agonist
EA200801614A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING MONTELUKAST
DK1974721T3 (en) Injectable sterile pharmaceutical composition with sodium piperacillin and sodium tazobactam as active substances
BRPI0614197B8 (en) pharmaceutically effective composition in a dosage form for peroral administration containing at least one of the active ingredients indomethacin and acemetacin, forms of administration, and use of the composition

Legal Events

Date Code Title Description
FA Abandonment or withdrawal